Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
NCT00005585
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which regimen of combination chemotherapy is more effective for childhood acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is comparing different regimens of combination chemotherapy to see how well they work in treating children with acute lymphoblastic leukemia.
Gender:
ALL
Ages:
Between 1 year and 9 years
Trial Updated:
04/04/2023
Locations: Driscoll Children's Hospital, Corpus Christi, Texas +10 locations
Conditions: Leukemia
Register for Updates
Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
NCT00005596
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which regimen of chemotherapy is more effective for acute lymphoblastic leukemia. PURPOSE: This randomized phase III trial is comparing four regimens of combination chemotherapy to see how well they work in treating children with newly diagnosed acute lymphoblastic leukemia.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
04/04/2023
Locations: Driscoll Children's Hospital, Corpus Christi, Texas +10 locations
Conditions: Leukemia
Register for Updates
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
NCT01036087
Completed
The goal of this clinical research study is to learn how effective the combination of chemotherapy including both panitumumab, Abraxane (nab-paclitaxel), and carboplatin (PNC) and fluorouracil, epirubicin, and cyclophosphamide (FEC) used before surgery for the treatment of IBC is. The safety of PNC combination will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/29/2023
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Breast Cancer
Register for Updates
Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan
NCT00496873
Completed
The goal of the clinical research study is to learn if treatment with a combination of three drugs, Cytoxan (cyclophosphamide), Rituxan (rituximab) and Nipent (pentostatin), will help to control the disease in patients with previously untreated non-Hodgkin's lymphoma, CLL, or bulky lymphoma. The safety of this treatment will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2023
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates
Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma
NCT02992743
Completed
This trial will evaluate safety and efficacy of Letetresgene autoleucel (GSK3377794) in participants with advanced myxoid/round cell liposarcoma or high-grade myxoid liposarcoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2023
Locations: GSK Investigational Site, Houston, Texas
Conditions: Neoplasms
Register for Updates
Scleroderma: Cyclophosphamide or Transplantation
NCT00114530
Completed
SCOT is a clinical research study designed for people with severe forms of scleroderma. SCOT stands for Scleroderma: Cyclophosphamide Or Transplantation. The SCOT study will compare the potential benefits of stem cell transplant and high-dose monthly cyclophosphamide (Cytoxan) in the treatment of scleroderma.
Gender:
ALL
Ages:
Between 18 years and 69 years
Trial Updated:
03/20/2023
Locations: University of Texas-Houston Medical School, Houston, Texas +1 locations
Conditions: Scleroderma, Systemic, Sclerosis, Autoimmune Disease
Register for Updates
TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
NCT04323657
Completed
TC-110 T cells are a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human CD19, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex. This is a Phase 1/2 open-label study to evaluate the safety of autologous genetically engineered TC-110 T cells in patients with aggressive NHL (DLBCL, PMBCL, TFL), high-risk indolent NHL (including MCL), or adul... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2023
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Register for Updates
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
NCT03412643
Unknown
This is a prospective, single arm, open label, multicenter interventional study designed to evaluate the efficacy of neoadjuvant chemotherapy with anti-HER2 antibodies in patients with HER2-negative invasive breast cancer who have abnormal HER2 signaling activity determined by the Celcuity CELx HER2 Signaling Function (HSF) testing.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/03/2023
Locations: Harris Health Systems-Smith Clinic, Houston, Texas +1 locations
Conditions: HER2-negative Breast Cancer
Register for Updates
TAC Versus TC for Adjuvant Breast Cancer
NCT00493870
Completed
The purpose of this research study is to find out what effects (good and bad) TC or TAC has on early stage HER2- breast cancer.
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
02/28/2023
Locations: Texas Cancer Center-Abilene (South), Abilene, Texas +30 locations
Conditions: Breast Cancer
Register for Updates
Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
NCT02960646
Completed
This pilot phase I trial studies the side effects of engineered donor stem cell transplant in treating patients with hematologic malignancies. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Using T cells specially selected from donor blood in the laboratory for transplant may stop this from happening.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/15/2023
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Aplastic Anemia, Chronic Myelomonocytic Leukemia, Myeloproliferative Neoplasm, Plasma Cell Myeloma, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Therapy-Related Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Register for Updates
Combination Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma
NCT00354835
Completed
This randomized phase III trial is studying two different combination chemotherapy regimens to compare how well they work when given together with radiation therapy in treating patients with newly diagnosed rhabdomyosarcoma. Drugs used in chemotherapy, such as vincristine sulfate, dactinomycin, cyclophosphamide, and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy... Read More
Gender:
ALL
Ages:
49 years and below
Trial Updated:
01/04/2023
Locations: Texas Tech University Health Sciences Center-Amarillo, Amarillo, Texas +11 locations
Conditions: Adult Rhabdomyosarcoma, Childhood Alveolar Rhabdomyosarcoma, Childhood Botryoid-Type Embryonal Rhabdomyosarcoma, Childhood Embryonal Rhabdomyosarcoma, Localized Childhood Soft Tissue Sarcoma, Rhabdomyosarcoma, Sarcoma, Stage I Adult Soft Tissue Sarcoma AJCC v7, Stage II Adult Soft Tissue Sarcoma AJCC v7, Stage III Adult Soft Tissue Sarcoma AJCC v7
Register for Updates
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
NCT04030195
Completed
This is a Phase 1/2a, nonrandomized, open-label, parallel assignment, single-dose, dose-escalation, and dose-expansion study to evaluate the safety and clinical activity of PBCAR20A in adult subjects with r/r B-cell NHL or r/r CLL/SLL.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/04/2023
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Non-Hodgkin's Lymphoma, Relapsed, Chronic Lymphoid Leukemia in Relapse, Non-Hodgkin's Lymphoma Refractory, Chronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-cell Chronic Lymphocytic Leukemia, B-cell Non Hodgkin Lymphoma, Small Lymphocytic Lymphoma
Register for Updates